Dr Suchitra Sundaram recalls a patient she treated over a decade ago and discusses how recent advances in targeted therapies have reshaped treatment strategies.

Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense ...

Dr Suchitra Sundaram describes critical disparities in DLBCL treatment, urging for equitable access to care and representation in clinical trials.

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...

MCL is type of B cell non-Hodgkin lymphoma, a cancer of the lymphatic system. Chemotherapy is the standard treatment, but relapse is common. Acalabrutinib, marketed under the brand name Calquence ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...